Skip to Content

Arbutus Biopharma Corp ABUS

Morningstar Rating
$3.36 +0.01 (0.30%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ABUS is trading at a 266% premium.
Price
$3.36
Fair Value
$3.95
Uncertainty
Very High
1-Star Price
$2.41
5-Star Price
$4.79
Economic Moat
Rbp
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABUS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.35
Day Range
$3.273.38
52-Week Range
$1.693.44
Bid/Ask
$3.36 / $3.35
Market Cap
$634.09 Mil
Volume/Avg
1.0 Mil / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
43.71
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
73

Comparables

Valuation

Metric
ABUS
AVIR
ENTA
Price/Earnings (Normalized)
Price/Book Value
5.270.591.52
Price/Sales
43.713.45
Price/Cash Flow
Price/Earnings
ABUS
AVIR
ENTA

Financial Strength

Metric
ABUS
AVIR
ENTA
Quick Ratio
6.4713.116.04
Current Ratio
6.6913.286.25
Interest Coverage
−262.44
Quick Ratio
ABUS
AVIR
ENTA

Profitability

Metric
ABUS
AVIR
ENTA
Return on Assets (Normalized)
−39.70%−20.62%−25.87%
Return on Equity (Normalized)
−52.72%−21.76%−50.83%
Return on Invested Capital (Normalized)
−56.43%−25.76%−46.23%
Return on Assets
ABUS
AVIR
ENTA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRGcngfjfnntZrqc$590.5 Bil
VRTX
Vertex Pharmaceuticals IncKnjdtsdvzMdgys$113.9 Bil
REGN
Regeneron Pharmaceuticals IncNtbtwhjzxHmzwxp$106.5 Bil
MRNA
Moderna IncFsynzfgjXvxn$58.7 Bil
BNTX
BioNTech SE ADRHstkrlrdhDjzr$22.7 Bil
ARGX
argenx SE ADRSxzyqpdtVnfl$21.8 Bil
ALNY
Alnylam Pharmaceuticals IncGwwbkpxgnCfnfg$19.0 Bil
BMRN
Biomarin Pharmaceutical IncLyjtnfyXynzmx$14.1 Bil
INCY
Incyte CorpMrmhbfjqCmkxp$12.8 Bil
TECH
Bio-Techne CorpJsxsfjtrySqcjp$12.4 Bil

Sponsor Center